Disease Domain | Count |
---|---|
Nervous System Diseases | 5 |
Endocrinology and Metabolic Disease | 4 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Therapeutic vaccine | 4 |
Small molecule drug | 2 |
Radiopharmaceuticals and diagnostic agent | 1 |
Diagnostic radiopharmaceuticals | 1 |
Target |
Mechanism APP inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism 5-HT2A receptor modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Dec 2024 |
Sponsor / Collaborator |
Start Date07 Feb 2014 |
Sponsor / Collaborator |
Start Date17 Jan 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
α-SC9 | Parkinson Disease More | Preclinical |
α-SC6 | Parkinson Disease More | Preclinical |
α-SC3 | Parkinson Disease More | Preclinical |
[18F]-R91150 ( 5-HT2A receptor ) | Neoplasms More | Preclinical |
PRI-002 ( APP x Cav2.2 ) | Neuralgia More | Preclinical |